Cited 0 times in
Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.